Copyright © Inderes 2011 - present. All rights reserved.

Mendus

8.462

 

SEK

 

-2.42 %

Corporate customer

IMMU

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

176 following
Compare
-2.42%
-8.46%
+3.36%
-7.42%
-19.1%
-29.72%
-85.95%
-95.36%
-93.61%

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

Read more
Market cap
426.14M SEK
Turnover
245.73K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 2024-11-20

Latest extensive report

Released: 2024-04-10

Financial calendar
13/2
2025

Annual report '24

9/5
2025

General meeting '24

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Mendus: We are discontinuing coverage
Research by
Antti Siltanen

Mendus: We are discontinuing coverage

We are discontinuing our coverage of Mendus as the company has terminated the equity research agreement. Consequently, we will no longer be giving a target price (was SEK 14) or a recommendation (was Accumulate) for the stock.

Mendus
Forum discussions
Ny uppdaterad analys efter Q2 rapport i fredags från Mendus! Inderes Mendus Q2'24: Ilixadencel to return to the clinical arena - Inderes For Mendus, Q2'24 marked the start of the pivotal CADENCE trial in acute myeloid leukemia (AML). The company also announced plans to restart clinical...
8/26/2024, 6:26 AM
by Jesper Hagman
4
Did an interview about Mendus with our analyst @antti.siltanen ! Inderes Mendus: Changing the course of cancer treatment - Inderes Mendus is a clinical-stage biotechnology company developing cellular immunotherapies for cancer. As a pre-revenue company, Mendus' risk profile is high...
4/16/2024, 6:49 AM
by Sara Antonacci
4
f the company interests you even a little, it’s definitely worth reading this. About 40 pages of easily digestible, high-quality information about the company, there’s no better ‘help’ for an investor. Inderes Keeping cancer in check - Inderes Mendus is a clinical-stage biotechnology...
4/10/2024, 6:00 AM
by börsen84
4
Mendus har släppt sin rapport för det andra kvartalet. I en intervju sammanfattar VD Erik Manting vad som hände under det andra kvartalet, presenterar de viktigaste framstegen i CADENCE-studien och berättar om den nya studien med läkemedlet Ilixadencel. Inderes Mendus Q2´24: The ...
8/24/2024, 11:56 AM
by börsen84
3
Read the latest report that was published today: Inderes AML development on track - Inderes Q1 Ethics Committee approval cleared the way for Mendus and partner ALLG to start patient recruitment for the CADENCE trial in acute myeloid leukemia (AML) in Q2’24. In parallel, Mendus is...
5/20/2024, 11:16 AM
by Jesper Hagman
3
CEO Erik Manting comments on the company’s Q1 and upcoming events in @antti.siltanen 's interview! Inderes Mendus Q1’24: Progress with main partnerships - Inderes Mendus made progress with main partnerships in Q1. CEO Erik Manting comments on the topic and other main events of Q1...
5/17/2024, 2:13 PM
by Sara Antonacci
3
JA! Äntligen är analysen här! Analysen får verkligen en stark läsrekommendation! Det går inte onoterat att Siltanen, som, det facto är Dr. i biomedicin verkligen kan sin sak. Kan inte annat än säga: dig in och läs! Att denna typ av material är tillgängligt för alla är en ren o sk...
4/10/2024, 8:17 AM
by Isa Hudd
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.